Poly Medicure Limited share price
NSE: POLYMED · ISIN INE205C01021
Key numbers
- Market cap
- ₹ 17,479 Cr
- Current price
- ₹ 1,724.40
- 52-week high / low
- ₹ 2,094 / 1,182
- Stock P/E
- 55.5
- Book value
- ₹ 306.4
- Dividend yield
- 0.20%
- ROCE
- 13.9%
- ROE
- 11.3%
- Debt to equity
- 0.11
- Sales growth (3 yrs)
- 19.1%
- Profit growth (3 yrs)
- 22.7%
- 1-year return
- -13.0%
About Poly Medicure Limited
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, including I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dialyzer, bloodlines and dialysis system. It also provides cardiology products PTFE wire, inflation device, Y-connector, manifold, introducer, IV Cannula, hydrophilic wire, guiding catheter, drug eluting stent, PTCA balloon dilation catheter, diagnostic catheter, and electrocardiograph electrodes; vaccular access products; oncology products; diagnostics products, including blood collection tubes, safety blood collection set, blood collection needles, and standard needle holder. In addition, the…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 403 | 444 | 494 | 535 | 525 |
| Operating profit | 106 | 115 | -46 | 110 | 125 |
| Net profit | 93 | 92 | 71 | 65 | 86 |
| EPS (₹) | 9.19 | 9.06 | 7.00 | 6.54 | 8.49 |
Concall summary (2026-08-14)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Revenue during this period almost went up by 2.75x to INR1,875 crores in FY26.
- On a stand-alone basis, we maintained revenue guidance of INR1,900 crores to INR2,000 crores with the domestic business expected to grow over 20% and international business growing by over 15%.
Growth & demand
- Stand-alone revenue for Q1 was INR431 crores, up 12.3% with domestic at INR146 crores, giving a growth of 16.2% and international at INR281.8 crores, giving a growth of 10%.
- And this year, as we have added some customers, on-boarded new customers, we were able to come back to our original growth or planned growth of 17% to 18% as we had forecasted in the beginning of the year.
Margins & costs
- I expect that our gross margin should continue to reflect on historic margin trend of 68% to 69% in the near term.
- We have guided a stand-alone EBITDA margin of 25% to 27% for FY27, but we have delivered 28%, 100 bps higher than the guided range.
Capex & expansion
- As you all know, PolyMed initiated operations in 1997 with an IPO of INR2.65 crores using which we set up our first plant.
- We did our first institutional fundraise, which resulted in multifold expansion of capacity.
Balance sheet & cash
- I mean PolyMed stand-alone does not have any debt other than the working capital debt.
- Just I wanted to understand how much is the operating leverage, which can still play out on a longer-term basis, not just 1, 2 quarter or 1 or 2 years.
Peers in Medical Instruments & Supplies
Data for information only, not investment advice. Prices end of day.